NVCR - NovoCure: Entering The Next Leaping Growth Phase
Summary
- A bear market is a highly opportunistic time for you to average down on fundamentally robust companies.
- NovoCure is a phenomenal growth stock that recently transitioned into a stalwart.
- Though NovoCure posted stellar growth in the previous few years, there are still substantial upsides ahead.
- The upcoming data release of four Phase 3 franchises would ultimately garner additional approval and thereby deliver leaping sales growth in the coming years.
- With the LUNAR trial data report coming as soon as 1Q next year, the stock is likely to run up again.
For further details see:
NovoCure: Entering The Next Leaping Growth Phase